Promising new combo targets tough head and neck cancer

NCT ID NCT07628855

Not yet recruiting Disease control Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—as a first treatment for advanced head and neck squamous cell carcinoma. It is for patients whose cancer has returned or spread and who cannot tolerate platinum-based chemotherapy. The study will enroll 30 participants to see if the combo can shrink tumors and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: becotatug vedotin (targeted cancer drug) combined with pucotenlimab (immunotherapy)
What this could lead to: If successful, this could offer a new first-line treatment option for people with advanced head and neck cancer who cannot tolerate standard platinum chemotherapy.
What could go wrong: This is a small, early-phase trial (30 people) with no control group, so results may not be definitive. The drug combination may cause side effects or fail to shrink tumors in many patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma hereditary nonpolyposis colon cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HNPCC

More trials for these conditions

Other studies related to the condition(s) this trial covers.